To investigate the effect of exposure to protease inhibitor (PI) therapy in utero on cord blood lipids in infants born to mothers enrolled in AIDS Clinical Trials Group protocol 5084, a prospective, multi-centre, observational study of antiretroviral therapy (ART) during pregnancy.
Methods
Clinical outcome was determined in 80 infants born to women treated with PIs and 73 infants born to women treated with other antiretrovirals during pregnancy. Cord blood serum from 117 of these infants was assayed for total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglyceride, apolipoprotein A1 (apoA1), apolipoprotein B100 (apoB) and lipoprotein (a). Covariates considered in the analysis included race/ethnicity, gestational age, infant gender, infant birth weight, mode of delivery, maternal tobacco and alcohol use, post-partum body mass index, and ART duration.
Results
Cord blood total and HDL cholesterol, triglyceride, apoA1, apoB, lipoprotein (a) and apoB/apoA1 ratio were not different between the two groups. Cord blood lipid levels in these HIV-exposed infants were similar to those reported in other neonatal cohorts. Controlling for race/ethnicity, infants born to women treated with PIs had higher LDL cholesterol than those born to women not treated with PIs (29 mg/dl versus 27 mg/dl, P=0.006).
Conclusion
Only LDL cholesterol was significantly higher in the cord blood of PI-exposed infants versus those not exposed to PIs in utero. As the difference between the two groups was small, the clinical relevance of the effect of maternal PI treatment on infant LDL cholesterol levels at birth is not clear.
References
1.
CDC.Achievements in public health: reduction in perinatal transmission of HIV infection – United States, 1985–2005.MMWR2006; 55: 592–597.
2.
European Collaborative Study.The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West.AIDS2006; 20: 1419–1427.
3.
BlancheS., TardieuM., RustinP.Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.Lancet1999; 354: 1084–1089.
4.
BroglyS.B., YlitaloN., MofensonL.M.In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.AIDS2007; 21: 929–938.
5.
NoguerraA., FortunyC., Munoz-AlmagroC.Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.Pediatr2004; 114: e598–e603.
6.
BulterysM., NesheimS., AbramsE.J.Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study.Ann NY Acad Sci2000; 918: 212–221.
7.
The Perinatal Safety Review Working Group.Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts.J Acquir Immune Defic Syndr2000; 25: 261–268.
8.
MelvinA.J., LennonS., MohanK., PurnellJ.Q.Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.AIDS Res Hum Retro2001; 17: 1117–1123.
9.
CarrA., SamarasK., ThorisdottirA., KaufmannG.R., ChisholmD.J., CooperD.A.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet1999; 353: 2093–2099.
10.
PeriardD., TelentiA., SudreP.Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.Circulation1999; 100: 700–705.
11.
KulasegaramR., PetersB.S., WierzbickiA.S.Dyslipidaemia and cardiovascular risk in HIV infection.Curr Med Res Opin2005; 21: 1717–1725.
12.
Perinatal HIV Guidelines Working Group.Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. (Updated 12 October 2006. Accessed 13 July 2007.) Available from http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
13.
NapoliC., GlassC.K., WitztumJ.L., DeutschR., D'ArmientoF.P., PalinskiW.Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study.Lancet1999; 354: 1234–1241.
14.
FonneboV., DahlL.B., MoeP.J., IngebretsenO.C.Does VLDL-LDL-cholesterol in cord serum predict future level of lipoproteins?Acta Paediatr Scand1991; 80: 780–785.
15.
BarkerD.J., MartynC.N., OsmondC., HalesC.N., FallC.H.Growth in utero and serum cholesterol concentrations in adult life.BMJ1993; 307: 1524–1527.
16.
KallioM.J., SalmenperaL., SiimesM.A., PerheentupaJ., MiettinenT.A.Tracking of serum cholesterol and lipoprotein levels from the first year of life.Pediatr1993; 91: 949–954.
17.
BastidaS., Sanchez-MunizF.J., CuenaR., PereaS., AragonesA.High density lipoprotein-cholesterol changes in children and high cholesterol levels at birth.Eur J Pediatr2002; 161: 94–98.
18.
RodieV.A., CaslakeM.J., StewartF.Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction.Atherosclerosis2004; 176: 181–187.
HittiJ., AndersenJ., McComseyG.Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.Am J Obstet Gynecol2007; 196: 331.e1–331.e7.
21.
LivingstonE.G., CohnS.E., YangY.Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy.Obstet Gynecol2007; 110: 391–397.
22.
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children.Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. (Updated 26 October 2006. Accessed 13 July 2007.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.
23.
Division of AIDS table for grading the severity of adult and pediatric adverse events. (Updated 23 December 2004. Accessed 7 April 2008.) Available from http://rcc.tech-res.com/tox_tables.htm.
24.
CotterA.M., GarciaA.G., DuthelyM.L., LukeB., O'SullivanM.Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?J Infect Dis2006; 193: 1195–1201.
25.
TuomalaR.E., ShapiroD.E., MofensonL.M.Antiretroviral therapy during pregnancy and the risk of an adverse outcome.N Engl J Med2002; 346: 1863–1870.
26.
BastidaS., CuestaC., PereaS., AragonesA., Sanchez-MunizF.J.Lipid and lipoprotein changes throughout the term-period in neonates from the Toledo Study.J Physiol Biochem1996; 52: 23–30.
27.
LoughreyC.M., RimmE., HeissG., RifaiN.Race and gender differences in cord blood lipoproteins.Atherosclerosis2000; 148: 57–65.
28.
KwiterovichP.O., VirgilD.G., GarrettE.S.Lipoprotein heterogeneity at birth: influences of gestational age and race on lipoprotein subclasses and Lp(a) lipoprotein.Ethn Dis2004; 14: 351–359.
29.
DiazM., LealC., Ramon y CajalJ.Cord blood lipoprotein-cholesterol: relationship birth weight and gestational age of newborns.Metabolism1989; 38: 435–438.
30.
BastidaS., Sanchez-MunizF.J., CuestaC., PereaS., AragonesA.Male and female cord blood lipoprotein profile differences throughout the term-period.J Perinat Med1997; 25: 184–191.
31.
MarzoliniC., RudinC., DecosterdL.Transplacental passage of protease inhibitors at delivery.AIDS2002; 16: 889–893.
32.
GingelmaierA., KurowskiM., KastnerM.Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.AIDS2006; 20: 1737–1743.
33.
GlueckC.J., HeckmanF., SchoenfeldM., SteinerP., PearceW.Neonatal familial type II hyperlipidemia: cord blood cholesterol in 1800 births.Metabolism1971; 20: 597–608.
34.
Sanchez-MunizF.J., BastidaS., PereaS., CuestaC., AragonesA.Low density lipoprotein in neonates with high cord serum cholesterol levels.Acta Pediatr1997; 86: 414–418.
35.
GoldsteinJ.L., AlbersJ.J., SchrottH.G., HazzardW.R., BiermanE.L., MotulskyA.G.Plasma lipid levels and coronary heart disease in adult relatives of newborns with normal and elevated cord blood lipids.Am J Hum Genet1974; 26: 727–735.
36.
RiddlerS.A., SmitE., ColeS.R.Impact of HIV infection and HAART on serum lipids in men.JAMA2003; 289: 2978–2982.
